patients with newly diagnosed EGPA receiving leukotriene inhibitors, we conditionally recommend continuing leukotriene inhibitors over discontinuing them. Following the introduction of leukotriene inhibitors, concerns were raised about a link with the development of EGPA. In subsequent retrospective studies, it was not concluded that there is a causal relationship between leukotriene inhibitors and EGPA Ungraded position statement: Use of leukotriene inhibitors is not contraindicated for